## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT8176242

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
AVELAS (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC	03/23/2023

#### **RECEIVING PARTY DATA**

Name:	AVELAS ACQUISITION CORPORATION
Street Address:	11099 NORTH TORREY PINES ROAD, SUITE 290
City:	LA JOLLA
State/Country:	CALIFORNIA
Postal Code:	92037

#### **PROPERTY NUMBERS Total: 17**

Property Type	Number
Application Number:	13819312
Application Number:	14736194
Application Number:	14235522
Application Number:	15006832
Application Number:	15132773
Application Number:	15295482
Application Number:	15806246
Application Number:	16228488
Application Number:	14764681
Application Number:	15685942
Application Number:	16264296
Application Number:	17302453
Application Number:	17930259
Application Number:	16603200
Application Number:	17048078
Application Number:	17048080
Application Number:	18248839

#### **CORRESPONDENCE DATA**

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

PATENT

508129062 REEL: 064958 FRAME: 0732

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** (415) 733-6000

**Email:** jhuddleston@goodwinlaw.com **Correspondent Name:** GOODWIN PROCTER LLP

Address Line 1: THREE EMBARCADERO CENTER
Address Line 4: SAN FRANCISCO, CALIFORNIA 94111

ATTORNEY DOCKET NUMBER:	AVS-000
NAME OF SUBMITTER:	JENNIFFER HUDDLESTON
SIGNATURE:	/Jenniffer C. Huddleston/
DATE SIGNED:	09/19/2023

#### **Total Attachments: 9**

source=Confirmatory Patent Assignment\_Avelas LLC to AAC\_Signed#page1.tif source=Confirmatory Patent Assignment\_Avelas LLC to AAC\_Signed#page2.tif source=Confirmatory Patent Assignment\_Avelas LLC to AAC\_Signed#page3.tif source=Confirmatory Patent Assignment\_Avelas LLC to AAC\_Signed#page4.tif source=Confirmatory Patent Assignment\_Avelas LLC to AAC\_Signed#page5.tif source=Confirmatory Patent Assignment\_Avelas LLC to AAC\_Signed#page6.tif source=Confirmatory Patent Assignment\_Avelas LLC to AAC\_Signed#page7.tif source=Confirmatory Patent Assignment\_Avelas LLC to AAC\_Signed#page8.tif source=Confirmatory Patent Assignment\_Avelas LLC to AAC\_Signed#page8.tif source=Confirmatory Patent Assignment\_Avelas LLC to AAC\_Signed#page9.tif

#### CONFIRMATORY CORPORATE ASSIGNMENT

THIS CONFIRMATORY ASSIGNMENT is made this \_\_\_\_\_day of March 2023, by and between Avelas Acquisition Corporation, a corporation organized under and pursuant to the laws of the State of Delaware having its principal place of business at 11099 North Torrey Pines Rd, Suite 290, La Jolla, California 92037 (hereinafter referred to as "Assignee") and Avelas (assignment for the benefit of creditors) LLC, a limited liability company organized under and pursuant to the laws of the State of California having its principal place of business at 3945 Freedom Circle, Suite 560, Santa Clara, California 95054, in its sole and limited capacity as assignee for the benefit of creditors of Avelas Biosciences, Inc. (hereinafter referred to as "Assignor").

WHEREAS, Assignor and Assignee entered into an Asset Purchase Agreement, dated December 13, 2022 (hereinafter, the "Agreement") under which Assignor agreed to and did assign the patents and patent applications listed in Purchased Assets Exhibit 1.2, Schedule 1 attached hereto (the "Application(s)") and any inventions contained therein;

WHEREAS, Assignor and Assignee desire to confirm Assignee's ownership of the entire right, title and interest in and to (a) said inventions and all embodiments thereof; and (b)(i) the Application(s), (ii) all United States, foreign, or international patent applications, including those filed under the Paris Convention for the Protection of Industrial Property, the Patent Cooperation Treaty or otherwise, that claim priority to or from the Application(s), including any divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application, (iii) each and every patent, utility model, or equivalent forms of protection thereto, including certification of invention, or inventor's certificate, granted or issued from any of the foregoing under subclause (ii), and (iv) each and every reissue, reexamination, renewal or extension of any kind of any patent of subclause (iii) (collectively, the "Patents").

NOW, THEREFORE, for good, valuable and sufficient consideration, receipt of which is hereby acknowledged by the Assignor, said Assignor confirms it has sold, assigned, transferred and conveyed unto said Assignee, its successors, legal representatives and assigns, or to the extent that such transfer has not been affected, does hereby sell, assign, transfer and

1 of 4

convey unto said Assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to (a) said inventions, (b) the Patents, including the right to claim priority to and from said Patents, and (c) all claims for past, present and future infringement of the Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patents.

Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treat. Such cooperation by said Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Patents; (d) for interference or other priority proceedings involving said inventions or Patents; and (e) for legal proceedings involving said inventions or Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions.

The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Assignor, their respective heirs, legal representatives and assigns.

Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

Said Assignor hereby requests that any Patents issuing or granting in the United States, any foreign country, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

2 of 4

This instrument will be interpreted and construed in accordance with the laws of the State of California without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the dates written below:

Assignor:

Avelas (assignment for the benefit of creditors) LLC, solely as assignee for the benefit of creditors of Avelas Biosciences, Inc.

Date:3/23/2023	Signature:	Name: Michael Maidy, in his sole and limited capacity
		1 /
		Title: as Manager of Avelas (assignment for the
Received and Agreed to by Assigne	ð:	benefit of creditors), LLC, the assignee for
Avelas Acquisition Corporation		Avelas Biosciences, Inc.
*		and the second s

Signature: Name: JULL なりやく Title: マニン かん チャル エア

# Purchased Assets Exhibit 1.2

	Patents

	Filed Patent				a_t_t_ton No.	Filing Date	Patent No.	Issue Date	Owner	Subject Matter
	Casa Number	Country	COMPOSITIONS FOR LABELING	Status	Application No.	Fillig Date	Patent No.	1250C Date		
1	AVS-005	EP	NERVES AND METHODS OF USE	Allowed	11822751.1	9/2/2011			Avelas Biosciences, Inc.	Nerve labeling
			COMPOSITIONS FOR LABELING			a /or /ooao		7/7/2015	Avelas Biosciences, Inc.	Nerve labeling
2	AVS-005		NERVES AND METHODS OF USE COMPOSITIONS FOR LABELING	Issued	13/819,312	4/25/2013	9,072,773	1/1/2013	AVE:85 DIDSCIERCES, INC.	rear or nabeling
3	AVS-005	<b>c</b> 1	NERVES AND METHODS OF USE	Issued	14/736,194	6/10/2015	9,353,154	5/31/2016	Avelas Biosciences, Inc.	Nerve labeling
			SELECTIVE DELIVERY							
_			MOLECULES AND METHODS OF	nois disse	2,841,249	7/27/2012			Avelas Biosciences, Inc.	AVB-620
4	AVS-006	CA	USE SELECTIVE DELIVERY	Pending	2,841,249	112112012			Aveias biosciences, nic.	7.0-020
			MOLECULES AND METHODS OF							
5	AVS-006	IP.		Granted	2014-523099	7/27/2012	6124150	4/14/2017	Avelas Biosciences, Inc.	AVB-620
			SELECTIVE DELIVERY MOLECULES AND METHODS OF							
6	AVS-006	AU		Granted	2012290318	7/27/2012	2012290318	12/15/2016	Avelas Biosciences, Inc.	AV8-620
			SELECTIVE DELIVERY							
			MOLECULES AND METHODS OF				ZL201280047936	11/15/2016	Avelas Biosciences, Inc.	AVB-620
7	AVS-005	CN	USE SELECTIVE DELIVERY	Granted	201280047936.9	7/27/2012	.9	1117012010	Aveias Biosciences, inc.	WA9-020
			MOLECULES AND METHODS OF			'				
·B	AVS-006	KR	USE	Granted	10-2014-7002685	7/27/2012	2004558	7/22/2019	Avelas Biosciences, Inc.	AV8-620
			SELECTIVE DELIVERY							
	AVS-006	EA	MOLECULES AND METHODS OF	Granted	201490385	7/27/2012	030795	9/28/2018	Avelas Biosciences, Inc.	AVB-620
9	MV3-000	-	SELECTIVE DELIVERY	U. drincu		-,2,,2022				
			MOLECULES AND METHODS OF							
10	AVS-006	мх	USE STATE OF LAND OF	Granted	MX/a/2014/001138	7/27/2012	350082	8/24/2017	Avelas Biosciences, Inc.	AVB-620
			SELECTIVE DELIVERY MOLECULES AND METHODS OF							
11	AVS-006	нк	USE	Granted	14110740.6	7/27/2012	1197184	9/27/2019	Avelas Biosciences, Inc.	AV8-620
			SELECTIVE DELIVERY							
			MOLECULES AND METHODS OF		14/235.522	9/18/2014	9 279 144	3/8/2016	Avelas Biosciences, Inc.	AVB-620
12	AV5-006	<del> </del>	SELECTIVE DELIVERY	Issued	14/235,322	3/10/2014	3,270,144	3/0/2020	A COLOR DE POSICIONE DE LA COLOR DE LA COL	
			MOLECULES AND METHODS OF							
13	AV5-006	C1		lssued	15/006,832	1/26/2016	9,371,367	6/21/2016	Avelas Biosciences, Inc.	AVB-620
			SELECTIVE DELIVERY MOLECULES AND METHODS OF				Î			
14	AV5-006	C2	USE	issued	15/132,773	4/19/2016	9.504,763	11/29/2016	Avelas Biosciences, Inc.	AVB-620
			SELECTIVE DELIVERY	1						
			MOLECULES AND METHODS OF				0.00000	17/17/2017	Avelas Biosciences, Inc.	AV8-620
15	AVS-006	C3	SELECTIVE DELIVERY	Issued	15/295,482	10/17/2016	9.840,537	12/12/2017	AVEIDS BIOSCIENCES, ITTL.	AVG-020
			MOLECULES AND METHODS OF							
16	AVS-006	<b>C4</b>	USE	Issued	15/806,246	11/7/2017	10,239,919	3/26/2019	Avelas Biosciences, Inc.	AVB-520
			SELECTIVE DELIVERY							
17	AVS-006	cs	MOLECULES AND METHODS OF USE	issued	16/228,488	12/20/2018	10.570.178	2/25/2020	Avelas Biosciences, Inc.	AVB-620
	1		SELECTIVE DELIVERY							
			MOLECULES AND METHODS OF	L	*********	7/27/2017	1225522	7/4/2019	Avelas Biosciences, Inc.	AVB-620
18	AVS-006	EP	SELECTIVE DELIVERY	Granted	12820320.5	7/27/2012	2/36555	7/4/201	MANCHES GROSCORES, INC.	JAVD-020
			MOLECULES AND METHODS OF							
19	AVS-006	G8	USE	Granted	12820320.5	7/27/2012	2736533	7/4/201	Avelas Biosciences, Inc.	AVB-620
			SELECTIVE DELIVERY							1
20	AVS-006	FR	MOLECULES AND METHODS OF	Granted	12820320.5	7/27/2013	2736533	7/4/201	8 Avelas Biosciences, Inc.	AVB-620
	1	T	SELECTIVE DELIVERY							
		l	MOLECULES AND METHODS OF						a Avalas Dias-1	AVR 520
21	AVS-006	DE	SELECTIVE DELIVERY	Granted	12820320.5	7/27/2012	2/30335	//4/201	B Avelas Biosciences, Inc.	AVB-620
			MOLECULES AND METHODS OF							
22_	AVS-006	п	USE	Granted	12820320.5	7/27/2013	2736533	7/4/201	B Avelas Biosciences, Inc.	AVB-620
			SELECTIVE DELIVERY							
23	AVS-006	23	MOLECULES AND METHODS OF	Granted	12820320.5	7/27/2013	2736533	7/4/201:	8 Avelas Biosciences, Inc.	AV8-620
- 63		1	SELECTIVE DELIVERY			1	7	T		
			MOLECULES AND METHODS OF							
24	AVS-006	BE	SELECTIVE DELIVERY	Granted	12820320.5	7/27/201	212736533	1/4/201	8 Avelas Il osciences, Inc.	AV8-620
			MOLECULES AND METHODS OF		1					
25	AVS-006	сн	USE	Granted	12820320.5	7/27/201	2 2736533	7/4/201	8 Avolas Biosciences, Inc.	AV8-620
			SELECTIVE DELIVERY							
26	AVE 005	TA	MOLECULES AND METHODS OF	Granted	12820320.5	7/27/201	2 2736533	7/4/201	8 Avelas Biosciences, Inc.	AVB-620
25	AVS-006	+	SELECTIVE DELIVERY	oranico .	ALDEVSEV-J	1,21,201		//-/201		T
			MOLECULES AND METHODS OF							1
27	AV5-006	NL	USE	Granted	12820320.5	7/27/201	2 2736533	7/4/201	8 Avelas Biosciences, Inc.	AVB-620
			SELECTIVE DELIVERY MOLECULES AND METHODS OF				***************************************		STOOM	
28	AVS-006	NO	USE	Granted	12820320.5	7/27/201	2 2736533	7/4/201	8 Avelas Biosciences, Inc.	AV8-620
	T	1	SELECTIVE DELIVERY			T	T			
		L_	MOLECULES AND METHODS OF		120202205	7/27/200	7736527	7/4/70-	8 Avelas Biosciences, Inc.	AV8-520
29	AVS-005	SE	USE	Granted	12820320,5	1 1/2/1/201	2 2736533	//4/201	ojaveids biosciences, IAC.	IVAD-BIN

		T	SELECTIVE DELIVERY					1		
			MOLECULES AND METHODS OF					74417070		AV8-620
30	AVS-006	Iξ		Granted	12820320.5	7/27/2012	2736533	7/4/2018	Avelas Biosciences, Inc	AVB-62U
			SELECTIVE DELIVERY				1			l
- I	AVE 006	DK	MOLECULES AND METHODS OF	Granted	12820320.5	7/27/2012	2736533	7/4/2018	Avelas Biosciences, Inc.	AVB-620
31	AVS-006	1	SELECTIVE DELIVERY							
			MOLECULES AND METHODS OF							
32	AV\$-006	FI		Granted	12820320.5	7/27/2012	2736533	7/4/2018	Avelas Biosciences, Inc.	AVB-520
			SELECTIVE DELIVERY					1	•	
			MOLECULES AND METHODS OF	Pending	18181420.3	7/27/2012		i.	Avelas Biosciences, Inc.	AVB-620
33	AVS-006	EPD1	SELECTIVE DELIVERY	remonte	10101410.5	METERS				
			MOLECULES AND METHODS OF							Cancer Imaging
34	AVS-008	EP	1	Pending	14746840.9	1/30/2014			Avelas Biosciences, inc	Compositons
		T	SELECTIVE DELIVERY							
-			MOLECULES AND METHODS OF					2/20/2020	turing Dinasianass tas	Cancer imaging Compositons
35	AVS-008	CN		Granted	201480019153.9	1/30/2014	105102484	3/10/2020	Avelas Biosciences, Inc.	COMPOSIDORS
1			SELECTIVE DELIVERY MOLECULES AND METHODS OF							Cancer Imaging
36	AVS-008	JP.		Granted	2015-556140	1/30/2014	65087B1	4/12/2019	Avelas Biosciences, Inc	Compositons
36	A43-000	- <del> '</del>	SELECTIVE DELIVERY							
			MOLECULES AND METHODS OF			1	0			Cancer Imaging
37	AVS-008	CA	USE	Granted	2899445	1/30/2014	2899448	10/26/2021	Avelas Biosciences, Inc.	Compositons
			SELECTIVE DELIVERY		1			1		Cancer Imaging
		1	MOLECULES AND METHODS OF	0	2479014	8/25/2021		1	Avelas Biosciences, Inc.	Compositons
38	AVS-008	CAD1	USE SELECTIVE DELIVERY	Pending	3128911	91 52 (4047	<del></del>			
			MOLECULES AND METHODS OF							Cancer Imaging
39	AV5-008	AU		Granted	2014212308	1/30/2014	2014212308	11/22/2018	Avelas Biosciences, Inc.	Compositons
33	1	<del> </del>	SELECTIVE DELIVERY							l
			MOLECULES AND METHODS OF						and the first section in the contract of the c	Cancer Imaging
40	AVS-008	EA		Granted	201591284	1/30/2014	031930	3/29/2019	Avelas Biosciences, Inc.	Campositons
	l	1	SELECTIVE DELIVERY							Cancer Imaging
			MOLECULES AND METHODS OF	Granted	10-2015-7022729	1/30/2014	2278630	7/12/2021	Avelas Biosciences, Inc.	Compositons
41	AV5-008	KR	SELECTIVE DELIVERY	Grantea	10-2015-7022725	2,50,252	1			
			MOLECULES AND METHODS OF							Cancer Imaging
42	AVS-008	KRD1	USE	Granted	10-2021-7021841	7/12/2021	2363779	2/11/2022	Avelas Biosciences, Inc.	Compositons
			SELECTIVE DELIVERY							Cancer Imaging
			MOLECULES AND METHODS OF			- 120/2014	20075	7/5/2010	Avelas Biosciences, Inc.	Compositons
43	AVS-008	MX	USE	Granted	MX/a/2015/009858	1/30/2014	356375	7/3/2013	Aveids biosciences, inc	COMPOSITORIS
		1	SELECTIVE DELIVERY MOLECULES AND METHODS OF							Cancer Imaging
44	AVS-008	IN	USE	Granted	6336/DELNP/2015	1/30/2014	375520	8/26/2021	Avelas Biosciences, Inc.	Compositons
44	AV3-008	-	SELECTIVE DELIVERY	ara						
			MOLECULES AND METHODS OF							Cancer Imaging
45	AVS-008	нк	USE	Pending	16105781.4	1/30/2014	<b></b>		Avelas Biosciences, Inc.	Compositons
			SELECTIVE DELIVERY							Cancer Imaging
	1		MOLECULES AND METHODS OF	issued	14/754,681	7/30/2015	9.782.498	10/10/2017	Avelas Biosciences, Inc.	Compositons
46	AVS-008		SELECTIVE DELIVERY	HISTORY	34/104343	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
			MOLECULES AND METHODS OF	1						Cancer Imaging
47	AVS-008	cı	USE	Issued	15/685.942	8/24/2017	10.226,539	3/12/2019	Avelas Biosciences, Inc.	Compositons
		144								
	1	-	SELECTIVE DELIVERY		1		4 1			C
			SELECTIVE DELIVERY MOLECULES AND METHODS OF		a c /m c a 20 c	1 (71 (701)	11053160	7/6/2021	Avalas Brossienses Inc.	Cancer imaging
48	AVS-008	C2	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	issued	16/264,296	1/31/2019	11052160	7/6/2023	Avelas Biosciences, Inc.	Cancer imaging Compositons
48	AVS-008		SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY		16/264,296	1/31/2015	11052160	7/6/2023	Avelas Biosciences, Inc.	
		a	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY MOLECULES AND METHODS OF		16/264,296	1/31/2015 8/18/2022		7/6/2023	Avelas Biosciences, Inc.	Compositons
48 49	AVS-008		SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY					7/6/2023		Compositons  Cancer Imaging
		a	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS	Pending	17/302.453	8/18/2022		7/6/2023	Avelas Biosciences, Inc	Compositons  Cancer Imaging Compositons
		a	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE	Pending				7/6/2023		Compositons  Cancer Imaging
49	AVS-008	α 3	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE  SELECTIVE DELIVERY MOLECULES AND METHODS OF USE  SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE  SELECTIVE DRUG DELIVERY	Pending Pending	17/302.453	8/18/2022		7/6/2923	Avelas Biosciences, Inc	Compositons  Cancer Imaging Compositons
49 50	AVS-008 AVS-009	C3	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE  SELECTIVE DELIVERY MOLECULES AND METHODS OF USE  SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE	Pending Pending	17/302,453 14788083.5	8/18/2022 4/22/2014	1	7/6/2023	Avelas Biosciences. Inc. Avelas Biosciences. Inc.	Compositons  Cancer Imaging Compositons
49	AVS-008	α 3	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY SELECTIVE DRUG DELIVERY OF USE OF USE SELECTIVE DRUG DELIVERY OF USE	Pending Pending	17/302.453	8/18/2022	1	7/6/2021	Avelas Biosciences, Inc	Compositons  Cancer Imaging Compositons  Therapeutics
49 50	AVS-008 AVS-009	C3	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE  SELECTIVE DELIVERY MOLECULES AND METHODS OF USE  SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE  SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE  SELECTIVE DRUG DELIVERY SELECTIVE DRUG DELIVERY SELECTIVE DRUG DELIVERY	Pending Pending	17/302,453 14788083.5	8/18/2022 4/22/2014 4/22/2014	4	7/6/2021	Avelas Biosciences, Inc.  Avelas Biosciences, Inc.  Avelas Biosciences, Inc.	Compositions  Cancer Imaging Compositions  Therapeutics  Therapeutics
49 50	AVS-008 AVS-009	C3	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY SELECTIVE DRUG DELIVERY OF USE OF USE SELECTIVE DRUG DELIVERY OF USE	Pending Pending	17/302,453 14788083.5	8/18/2022 4/22/2014	4	7/6/2023	Avelas Biosciences. Inc. Avelas Biosciences. Inc.	Compositons  Cancer Imaging Compositons  Therapeutics
49 50 51	AVS-008 AVS-009	C3 EP	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE  SELECTIVE DELIVERY MOLECULES AND METHODS OF USE  SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE  SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE  SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE  NERVE LABELING	Pending Pending Pending	17/302.453 14788083.5 16110317.7	8/18/2022 4/22/2014 4/22/2014	4	7/6/2023	Avelas Biosciences, Inc.  Avelas Biosciences, Inc.  Avelas Biosciences, Inc.	Compositions  Cancer Imaging Compositions  Therapeutics  Therapeutics
49 50 51	AVS-009 AVS-009	C2 C3 EP HK	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DRUG DÉLIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DÉLIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE NERVE LABELING COMPOSITIONS AND METHODS OF USE NERVE LABELING COMPOSITIONS AND USES	Pending Pending Pending	17/302,453 14788083.5 16110317.7	8/18/2022 4/22/2014 4/22/2014 9/7/2022			Avelas Biosciences, Inc.  Avelas Biosciences, Inc.  Avelas Biosciences, Inc.  Avelas Biosciences, Inc.	Compositions  Cancer Imaging Compositions  Therapeutics  Therapeutics  Therapeutics
49 50 51	AVS-008 AVS-009	C3 EP	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE NERVE LABELING COMPOSITIONS AND USES THEREOF	Pending Pending Pending	17/302.453 14788083.5 16110317.7	8/18/2022 4/22/2014 4/22/2014			Avelas Biosciences, Inc.  Avelas Biosciences, Inc.  Avelas Biosciences, Inc.	Compositions  Cancer Imaging Compositions  Therapeutics  Therapeutics
49 50 51	AVS-009 AVS-009	C2 C3 EP HK	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE  SELECTIVE DELIVERY MOLECULES AND METHODS OF USE  SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE  SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE  SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE  NERVE LABELING COMPOSITIONS AND USES THEREOF NERVE LABELING	Pending Pending Pending	17/302,453 14788083.5 16110317.7	8/18/2022 4/22/2014 4/22/2014 9/7/2022			Avelas Biosciences, Inc.  Avelas Biosciences, Inc.  Avelas Biosciences, Inc.  Avelas Biosciences, Inc.	Compositions  Cancer Imaging Compositions  Therapeutics  Therapeutics  Therapeutics  Therapeutics  Nerve labeling
50 51 52	AVS-008 AVS-009 AVS-009 AVS-010	C2 C3 EP HK	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE NERVE LABELING COMPOSITIONS AND USES THEREOF NERVE LABELING COMPOSITIONS AND USES THEREOF NERVE LABELING COMPOSITIONS AND USES	Pending Pending Pending Pending	17/302,453 14788083.5 16110317.7	8/18/2022 4/22/2014 4/22/2014 9/7/2022	10994017		Avelas Biosciences, Inc.  Avelas Biosciences, Inc.  Avelas Biosciences, Inc.  Avelas Biosciences, Inc.	Compositions  Cancer Imaging Compositions  Therapeutics  Therapeutics  Therapeutics
49 50 51	AVS-009 AVS-009	C2 C3 EP HK	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE  SELECTIVE DELIVERY MOLECULES AND METHODS OF USE  SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE  SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE  SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE  NERVE LABELING COMPOSITIONS AND USES THEREOF NERVE LABELING	Pending Pending Pending	17/302,453 14788083.5 16110317.7 17/930259 16/466,259	8/18/2022 4/22/2014 4/22/2014 9/7/2022	10994017		Avelas Biosciences, Inc.	Compositions  Cancer Imaging Compositions  Therapeutics  Therapeutics  Therapeutics  Therapeutics  Nerve labeling
50 51 52	AVS-008 AVS-009 AVS-009 AVS-010	C2 C3 EP HK	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE NERVE LABELING COMPOSITIONS AND USES THEREOF NERVE LABELING COMPOSITIONS AND USES THEREOF NERVE LABELING COMPOSITIONS AND USES THEREOF	Pending Pending Pending Pending	17/302,453 14788083.5 16110317.7 17/930259 16/466,259	8/18/2022 4/22/2014 4/22/2014 9/7/202: 6/3/2014	1 10994017		Avelas Biosciences, Inc.	Compositions  Cancer Imaging Compositions  Therapeutics  Therapeutics  Therapeutics  Nerve labeling
50 51 52	AVS-008 AVS-009 AVS-009 AVS-010	C2 C3 EP HK	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE NERVE LABELING COMPOSITIONS AND USES THEREOF NERVE LABELING COMPOSITIONS AND USES	Pending Pending Pending Pending	17/302,453 14788083.5 16110317.7 17/930259 16/466,259	8/18/2022 4/22/2014 4/22/2014 9/7/2022	1 10994017		Avelas Biosciences, Inc.	Compositions  Cancer Imaging Compositions  Therapeutics  Therapeutics  Therapeutics  Therapeutics  Nerve labeling
50 51 52 53 54	AVS-008  AVS-009  AVS-009  AVS-010  AVS-010	C2	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE  SELECTIVE DELIVERY MOLECULES AND METHODS OF USE  SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE  SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE  NETY OF USE NETY LABELING COMPOSITIONS AND USES THEREOF NERVE LABELING COMPOSITIONS AND USES THEREOF RETY LABELING COMPOSITIONS AND USES THEREOF RETY LABELING COMPOSITIONS AND USES THEREOF RETY LABELING COMPOSITIONS AND USES THEREOF	Pending Pending Pending  Pending  Ssaued  Pending  Pending	17/302.453  14788083.5  16110317.7  17/930259  16/466.259  17/249.006	8/18/2022 4/22/2014 4/22/2014 9/7/202; 6/3/2014 2/17/202; 12/1/201	1 10994017		Avelas Biosciences, Inc.	Compositions  Cancer Imaging Compositions  Therapeutics  Therapeutics  Therapeutics  Nerve labeling  Nerve labeling
49 50 51 52 53	AVS-009  AVS-009  AVS-010  AVS-010	C2 C3 EP HK C3	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE NERVE LABELING COMPOSITIONS AND USES THEREOF NERVE LABELING COMPOSITIONS AND USES THEREOF NERVE LABELING COMPOSITIONS AND USES THEREOF RETVE LABELING COMPOSITIONS AND USES THEREOF RETVE LABELING COMPOSITIONS AND USES THEREOF RETVE LABELING COMPOSITIONS AND USES THEREOF RATIOMETRIC FLUORESCENCE INAGRING METHODS	Pending Pending Pending Stated	17/302,453 14788083.5 16110317.7 17/930259 18/466.259	8/18/2022 4/22/2014 4/22/2014 9/7/202; 6/3/2014 2/17/202; 12/1/201	1 10994017		Avelas Biosciences, Inc.	Compositions  Cancer Imaging Compositions  Therapeutics  Therapeutics  Therapeutics  Nerve labeling  Nerve labeling
50 51 52 53 54 55	AVS-009  AVS-009  AVS-009  AVS-010  AVS-010  AVS-011	C2 C3 EP HK C3 US C1 EP EPD1	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE NERVE LABELING COMPOSITIONS AND USES THEREOF RETURN LABELING COMPOSITIONS AND USES THEREOF RETURN LABELING COMPOSITIONS AND USES THEREOF RATIOMETRIC FLUORESCENCE IMAGING METHODS RATIOMETRIC FLUORESCENCE	Pending Pending Pending Pending Pending Pending Pending Pending	17/302,453 14788083.5 16110317.7 17/930259 15/466,259 17/249,006 17875429.7 21164870.4	8/18/2022 4/22/2014 4/22/2014 9/7/2022 6/3/2019 2/17/202 12/1/201 3/25/202	1 10994017		Avelas Biosciences, Inc.	Compositions Cancer Imaging Compositions Therapeutics Therapeutics Therapeutics Nerve labeling Nerve labeling Nerve labeling Rallometric imaging
50 51 52 53 54	AVS-008  AVS-009  AVS-009  AVS-010  AVS-010	C2	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DRUG DÉLIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DÉLIVERY COMPOSITIONS AND METHODS OF USE NERVE LABELING COMPOSITIONS AND METHODS OF USE NERVE LABELING COMPOSITIONS AND USES THEREOF REVIEL ABELING COMPOSITIONS AND USES THEREOF REVIEL ABELING COMPOSITIONS AND USES THEREOF RETIOMETRIC FLUORESCENCE IMAGING METHODS RATIOMETRIC FLUORESCENCE IMAGING METHODS	Pending Pending Pending  Pending  Ssaued  Pending  Pending	17/302.453  14788083.5  16110317.7  17/930259  16/466.259  17/249.006	8/18/2022 4/22/2014 4/22/2014 9/7/202; 6/3/2014 2/17/202; 12/1/201	1 10994017		Avelas Biosciences, Inc.	Compositions  Cancer Imaging Compositions  Therapeutics  Therapeutics  Therapeutics  Nerve labeling  Nerve labeling  Nerve labeling  Rallometric imaging
49 50 51 52 53 54 55 56 57	AVS-009  AVS-009  AVS-010  AVS-010  AVS-011  AVS-011	C2 C3 EP HK C3 US C1 EP EPD1 KR	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE NERVE LABELING COMPOSITIONS AND USES THEREOF NERVE LABELING COMPOSITIONS AND USES THEREOF NERVE LABELING COMPOSITIONS AND USES THEREOF RETURN LABELING COMPOSITIONS AND USES THEREOF RETURN LABELING COMPOSITIONS AND USES THEREOF RATIOMETRIC FLUORESCENCE IMAGING METHODS RATIOMETRIC FLUORESCENCE IMAGING METHODS RATIOMETRIC FLUORESCENCE IMAGING METHODS RATIOMETRIC FLUORESCENCE IMAGING METHODS RATIOMETRIC FLUORESCENCE	Pending Pending Saued Pending Pending Pending Pending Pending	17/302,453 14788083.5 16110317.7 17/930259 16/466.259 17/249,006 17875429.7 21164870.4	8/18/2022 4/22/2014 4/22/2014 9/7/2022 6/3/2019 2/17/202 12/1/201 3/25/202	10894017		Avelas Biosciences, Inc.	Compositions  Cancer Imaging Compositions  Therapeutics  Therapeutics  Therapeutics  Nerve labeling  Nerve labeling  Residemetric imaging Ratiometric imaging Ratiometric imaging
50 51 52 53 54 55	AVS-009  AVS-009  AVS-009  AVS-010  AVS-010  AVS-011	C2 C3 EP HK C3 US C1 EP EPD1	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DRUG DÉLIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DÉLIVERY COMPOSITIONS AND METHODS OF USE NERVE LABELING COMPOSITIONS AND METHODS OF USE NERVE LABELING COMPOSITIONS AND USES THEREOF REVIEL ABELING COMPOSITIONS AND USES THEREOF REVIEL ABELING COMPOSITIONS AND USES THEREOF RETIOMETRIC FLUORESCENCE IMAGING METHODS RATIOMETRIC FLUORESCENCE IMAGING METHODS	Pending Pending Pending Pending Pending Pending Pending Pending	17/302,453 14788083.5 16110317.7 17/930259 15/466,259 17/249,006 17875429.7 21164870.4	8/18/2022 4/22/2014 4/22/2014 9/7/202: 6/3/2014 2/17/202: 12/1/201 3/25/202 4/5/201	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		Avelas Biosciences, Inc.	Compositions  Cancer Imaging Compositions  Therapeutics  Therapeutics  Therapeutics  Nerve labeling  Nerve labeling  Nerve labeling  Ratiometric imaging  Ratiometric imaging
50 51 52 53 54 55 56 57	AVS-009  AVS-009  AVS-010  AVS-010  AVS-011  AVS-011	C2 C3 EP HK C3 US C1 EP EPD1 KR	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE NERVE LABELING COMPOSITIONS AND USES THEREOF NERVE LABELING COMPOSITIONS AND USES THEREOF NERVE LABELING COMPOSITIONS AND USES THEREOF RATIOMETRIC FLUORESCENCE IMAGING METHODS	Pending Pending Saued Pending Pending Pending Pending Pending	17/302,453 14788083.5 16110317.7 17/930259 16/466.259 17/249,006 17875429.7 21164870.4	8/18/2022 4/22/2014 4/22/2014 9/7/202: 6/3/201: 2/17/202: 12/1/201: 3/25/702 4/5/201	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		Avelas Biosciences, Inc.	Compositions  Cancer Imaging Compositions  Therapeutics  Therapeutics  Therapeutics  Nerve labeling  Nerve labeling  Nerve labeling  Ratiometric imaging  Ratiometric imaging
50 51 52 53 54 55 56 57 58	AVS-009  AVS-009  AVS-010  AVS-010  AVS-011  AVS-011  AVS-011	C2 C3 EP HK C3 U5 C1 EP EPD1 KR CN	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE NERVE LABELING COMPOSITIONS AND USES THEREOF NERVE LABELING COMPOSITIONS AND USES THEREOF NERVE LABELING COMPOSITIONS AND USES THEREOF RATIOMETRIC FLUORESCENCE LIMAGING METHODS	Pending Pending Pending Fending Pending Pending Pending Pending Pending Pending Pending Pending	17/302,453  14788083.5  16110317.7  17/930259  15/466,259  17/249,006  17875429.7  21164870.4  10-2019-7033078  2018800381739  42021040708.6	8/18/2022 4/22/2014 4/22/2014 9/7/2022 6/3/2019 2/17/202 12/1/201 3/25/202 4/5/201 4/5/201 10/19/202	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	5/4/202	Avelas Biosciences, Inc.	Compositions  Cancer Imaging Compositions  Therapeutics  Therapeutics  Therapeutics  Nerve labeling  Nerve labeling  Nerve labeling  Ratiometric imaging Ratiometric imaging Ratiometric imaging
50 51 52 53 54 55 56 57 58	AVS-009  AVS-009  AVS-010  AVS-010  AVS-011  AVS-011  AVS-011	C2 C3 EP HK C3 U5 C1 EP EPD1 KR CN	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DELIVERY MOLECULES AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE NERVE LABELING COMPOSITIONS AND USES THEREOF NERVE LABELING COMPOSITIONS AND USES THEREOF NERVE LABELING COMPOSITIONS AND USES THEREOF RATIOMETRIC FLUORESCENCE IMAGING METHODS	Pending	17/302,453  14788083.5  16110317.7  17/930259  15/466,259  17/249,006  17875429.7  21164870.4  10-2019-7033078  2018800381739	8/18/2022 4/22/2014 4/22/2014 9/7/202: 6/3/2014 2/17/202: 12/1/201 3/25/202 4/5/201	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	5/4/202	Avelas Biosciences, Inc.	Compositions  Cancer Imaging Compositions  Therapeutics  Therapeutics  Therapeutics  Nerve labeling  Nerve labeling  Nerve labeling  Ratiometric imaging  Ratiometric imaging

			COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY					
62	AVS-012	us	OF THERAPUTIC AND IMAGING	Pending	17/048.078	10/15/2020	Avelas Biosciences, Ir	c. Therapeutics
			COMPOSITIONS AND METHODS					
			FOR THE SELECTIVE DELIVERY					
			OF THERAPUTIC AND IMAGING		1	4	Avelas Biosciences, Ir	r. Therapeutics
63	AVS-012	EP		Pending	19789295.3	11/16/2020	Aveias biosciences, ir	C' lifetahennea
		i	COMPOSITIONS AND METHODS	l	1			
			FOR THE SELECTIVE DELIVERY	ł	1 1	000		
			OF THERAPUTIC AND IMAGING		1 1			Therapeutics
64	AVS-012	нк	AGENTS	Pending	62021036762	8/11/2021	Avelas Biosciences, Ir	ic. Therapeutics
	1		SELECTIVE DELIVERY OF					
			THERAPUTIC AND IMAGING					
65	AVS-013	us	AGENTS	Pending	17/048,080	10/15/2020	Avelas Biosciences, I	r. Therapeutics
			METHODS OF SURGICALLY	1		1		
66	AVS.014	wa	REMOVING TUMOR CELLS	Pending	PCT/U52021/054313	10/8/2021	Avelas Bioscionses, la	c. AVB-620

### California all-purpose acknowledgment

A notary public or other officer completing this certificate document to which this certificate is attached, and not the	ate verifies only the identity of the individual who signed the ne truthfulness, accuracy, or validity of that document.					
State of California ) County of San Diego ) On March 9, 2023 before me, (  Date  personally appeared	Christing E. Soyers, Notoxy Public Here Insert Name and Title of the Officer Lichton Name(s) of Signer(s)					
subscribed to the within instrument and acknow	evidence to be the person(s) whose name(s) is/are ledged to me that he/she/they executed the same in is/hen/their signature(s) on the instrument the person(e), cted, executed the instrument.					
	I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.					
	WITNESS my hand and official seal.					
CHRISTINE E. SAYERS	01 12 0					
Notary Public - California	- Unstino Parera					
Commission # 2364183 My Comm. Expires Jul 5, 2025	Signature Signature of Notary Public					
Place Notary Seal Above						
	TIONAL					
Though this section is optional, completing this	information can deter alteration of the document or sometons form to an unintended document.					
Description of Attached Document						
Title or Type of Document:	Document Date:					
Number of Pages: Signer(s) Other The	an Named Above:					
Capacity(ies) Claimed by Signer(s)						
Signer's Name: Corporate Officer — Title(s):	Signer's Name:					
	☐ Corporate Officer — Title(s):					
☐ Partner — ☐ Limited ☐ General	☐ Partner — ☐ Limited ☐ General ☐ Individual ☐ Attorney in Fact					
☐ Individual ☐ Attorney in Fact ☐ Guardian or Conservator	☐ Trustee ☐ Guardian or Conservator					
Other:						
Signer Is Representing:	Signer Is Representing:					
	A					
©2014 National Notary Association • www.NationalNot	ary.org • 1-800-US NOTARY (1-800-876-6827) Item #5907					

A notary public or other officer completing this converifies only the identity of the individual who sign document to which this certificate is attached, attruthfulness, accuracy, or validity of that documents	gned the not the
instrument and acknowledged to me that he/sh	)SS  ne Constant Public, personally appeared vevidence to be the person(s) whose name(s) is/are subscribed to the within the executed the same in his/her/their authorized capacity(ies), and that by person(s), or the entity upon behalf of which the person(s) acted, executed the
I certify under PENALTY OF PERJURY under the la WITNESS my hand and official seal.  Signature	CARISSA ANNE KOZACEK Notary Public - California Santa Clara County Commission # 2292012 My Comm. Expires Jun 8, 2023
	This area for official notarial seal.
OPTIONAL SECTION	- NOT PART OF NOTARY ACKNOWLEDGEMENT
•	PACITY CLAIMED BY SIGNER
Though statute does not require the Notary to fill documents.  INDIVIDUAL  CORPORATE OFFICER(S) TITLE(S)	in the data below, doing so may prove invaluable to persons relying on the
PARTNER(S) LIMITED	GENERAL
ATTORNEY-IN-FACT TRUSTEE(S) GUARDIAN/CONSERVATOR OTHER SIGNER IS REPRESENTING:	
Name of Person or Entity	Name of Person or Entity
OPTIONAL SECTION	- NOT PART OF NOTARY ACKNOWLEDGEMENT required by law, it could prevent fraudulent reattachment of this form.
	E ATTACHED TO THE DOCUMENT DESCRIBED BELOW
TITLE OR TYPE OF DOCUMENT:	
NUMBER OF PAGES	DATE OF DOCUMENT
SIGNER(S) OTHER THAN NAMED ABOVE	

CALIFORNIA ALL-PURPOSE ACKNOWLEDGEMENT

PATENT REEL: 064958 FRAME: 0742

Reproduced by First American Title Company 11/2007

RECORDED: 09/19/2023